P53, MDM-2, BAX and BCL-2 and Drug Resistance in Chronic Lymphocytic Leukemia

References

• O'Brien S., Del Giglio A., Keating M. Advances in the biology and treatment of B-cell chronic lymphocytic leukemia. Blood 1995; 85: 307–318
   PubMed Web of Science ®Google Scholar
• Begleiter A., Goldenberg G. J., Anhalt C. D., Lee K., Mowat M. R., Israels L. G., Johnston J. B. Mechanisms of resistance to chlorambucil in CLL. Leuk. Res. 1991; 15: 1019–1027
   PubMed Web of Science ®Google Scholar
• Saven A., Lawrence L. D. 2-Chlorode-oxyadenosine: A newer purine analog active in the treatment of indolent lymphoid malignancies. Am. J. Med. 1994; 120: 784–791
   Google Scholar
• Alessi-Severini S., Gati W. P., Belch A. R., Paterson A. R. P. Intracellular pharmacokinetics of 2-chloro-deoxyadenosine in leukemia cells from patients with chronic lymphocytic leukemia. Leukemia 1995; 9: 1674–1679
   PubMed Web of Science ®Google Scholar
• Begleiter A., Verburg L., Ashique A., Lee K., Israels L. G., Mowat M. R. A., Johnston J. B. Comparison of antitumor activities of 2-chlorodeoxyadenosine and 9–β-arabi-nosyl-2-fluoroadenine in chronic lymphocytic leukemia and marrow cells in vitro. Leukemia 1995; 9: 1875–1881
   PubMed Web of Science ®Google Scholar
• Carrera C. J., Terai T., Lotz M., Curd J. G., Piro L. D., Beutler E., Carson D. A. Potent toxicity of 2-chlorodeoxyadeuosine toward human monocytes in vitro. in vivo. J. Clin. Invest. 1990; 86: 1480–1488
   PubMed Web of Science ®Google Scholar
• Robertson L. E., Chubb S., Meyn R. E., Story M., Ford R., Hittelman W. N., Plunkett W. Induction of apop-totic cell death in chronic lymphocytic leukemia by 2-chloro-2′-deoxyadenosine and 9–β-D-arabinosyl-2-fluoroadenine. Blood 1993; 81: 143–150
   PubMed Web of Science ®Google Scholar
• Begleiter A., Lee K., Israels L. G., Mowat M. R. A., Johnston J. B. Chlorambucil induced apoptosis in chronic lymphocytic leukemia (CLL) and its relationship to clinical efficacy. Leukemia 1994; 1: 103–106, 8 Suppl
   Google Scholar
• Selivanova G., Wiman K. G. p53: A cell cycle regulator activated by DNA damage. Advances in Cancer Res 1995; 66: 143–180
   PubMed Web of Science ®Google Scholar
• El Deiry W. S., Tokino T., Velculescu V. E., Levy D. B., Parsons R., Trent J. M., Lin D., Mercer K. W., Kinder E. W., Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell 1993; 75: 817–825
   PubMed Web of Science ®Google Scholar
• Waga S., Hannon G. I., Beach D., Stillman B. The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature 1994; 369: 574–578
   PubMed Web of Science ®Google Scholar
• Chen C. Y., Oliner J. D., Zhan Q., Fornace A. J., Jr, Vogelstein B., Kastan M. B. Interactions between p53 and MDM2 in a mammalian cell cycle checkpoint pathway. Proc. Natl. Acad. Sci. U. S. A. 1994; 91: 2684–2688
   PubMed Web of Science ®Google Scholar
• Price B. D., Park S. J. DNA damage increases the levels of mdm-2 messenger RNA in wtp53 human cells. Cancer Res. 1994; 54: 896–899
   PubMed Web of Science ®Google Scholar
• Miyashita T., Krajewski S., Krajewska M., Wang H. G., Lin H. K., Liebermann D. A., Hoffman B., Reed J. C. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 1994; 9: 1799–1805
   PubMed Web of Science ®Google Scholar
• Lowe S. W., Ruley H. E., Jacks T., Housman D. E. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993; 74: 957–967
   PubMed Web of Science ®Google Scholar
• Fisher D. E. Apoptosis in cancer therapy: crossing the threshold. Cell 1994; 78: 539–542
   PubMed Web of Science ®Google Scholar
• Lowe S. W., Schmitt E. M., Smith S. W., Osborne B. A., Jacks T. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 1993; 362: 847–849
   PubMed Web of Science ®Google Scholar
• Fan S., El-Deiry W. S., Bae I., Freeman J., Jondle D., Bhatia K., Fornace A. J., Jr, Magrath I., Kohn K. W., O'Connor M. p53 mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents. Cancer Res. 1994; 54: 5824–5830
   PubMed Web of Science ®Google Scholar
• Fisher D. E., Bodis S., Lowe S., Takemoto C., Housman D., Jacks T. Restoration of apoptosis in p53 deficient tumor cells. Blood 1994; 84(Suppl)111a
   PubMedGoogle Scholar
• El Rouby S., Thomas A., Costin D., Rosenberg C. R., Potmesil M., Silber R., Newcomb E. W. p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDRl/MDR3 gene expression. Blood 1993; 82: 3452–3459
   PubMed Web of Science ®Google Scholar
• Dohner H., Fischer K., Bentz M., Hansen K., Benner A., Cabot G., Diehl D., Schlenk R., Coy J., Stilgenbauer S., Volkman M., Galle P. R., Poustka A., Hunstein W., Lichter P. p53 gene deletion predicts for poor survival therapy with purine analogs in chronic B-cell leukemias. Blood 1995; 85: 1580–1589
   PubMed Web of Science ®Google Scholar
• Oltvai Z. N., Milliman C. L., Korsmeyer S. J. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 1993; 74: 609–619
   PubMed Web of Science ®Google Scholar
• Boise L. H., Gonzalez-Garcia M., Postema C. E., Ding L., Lindsten T., Turka L. A., Mao X., Nunez G., Thompson C. B. Bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 1993; 74: 597–608
   PubMed Web of Science ®Google Scholar
• Yang E., Zha J., Jockel J., Boise L. H., Thompson C. B., Korsmeyer S. J. Bad, a heterodimeric partner for Bcl-XL and Bcl-2, displaces Bax and promotes cell death. Cell 1995; 80: 285–291
   PubMed Web of Science ®Google Scholar
• Reed J. C. Bcl-2 and the regulation of programmed cell death. J. Cell Biol. 1994; 124: 1–6
   PubMed Web of Science ®Google Scholar
• Takayama S., Sato T., Krajewski S., Kochel K., Irie S., Millan J. A., Reed J. C. Cloning and functional analysis of BAG-1: A novel Bcl-2 binding protein with anti-cell death activity. Cell 1995; 80: 279–284
   PubMed Web of Science ®Google Scholar
• Haldar S., Jena N., Croce C. M. Inactivation of bcl-2 by phosphorylation. Proc. Natl. Acad. Sci. USA 1995; 92: 4507–4511
   PubMed Web of Science ®Google Scholar
• Sentman C. L., Shutter J. R., Hockenberry D., Kanagawa O., Korsmeyer S. J. Bcl-2 inhibits multiple forms of apoptosis but not negative selection in thymocytes. Cell 1991; 67: 879–888
   PubMed Web of Science ®Google Scholar
• Fisher T. C., Milner A. E., Gregory C. D., Jackman A. L., Aheme G. W., Hartley J. A., Dive C., Hickman J. A. Bcl-2 modulation of apoptosis induced by anticancer drugs: resistance to thymidylate stress is independent of classical resistance pathways. Cancer Res. 1993; 53: 3321–3326
   PubMed Web of Science ®Google Scholar
• Minn A. J., Rudin C. M., Boise L. H., Thompson C. B. Expression of bcl-x, can confer a multidrug resistance phenotype. Blood 1995; 86: 1903–1910
   PubMed Web of Science ®Google Scholar
• Schena M., Larsson L.-G., Gottardi D., Gaidano G., Calsson M., Nilsson K., Caligaris-Cappio F. Growth- and differentiation-associated expression of bcl-2 in B-chronic lymphocytic leukemia cells. Blood 1992; 79: 2981–2989
   PubMed Web of Science ®Google Scholar
• Hanada M., Delia D., Aiello A., Stadtmauer E., Reed J. C. Bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia. Blood 1993; 82: 1820–1828
   PubMed Web of Science ®Google Scholar
• Watanabe T., Hotta T., Ichikawa A., Kinoshita T., Nagai H., Uchida T., Murate T., Saito H. The mdm2 oncogene overexpression in chronic lymphocytic leukema and low-grade lymphoma of B-cell origin. Blood 1994; 84: 3158–3165
   PubMed Web of Science ®Google Scholar
• Johnston J. B., Lee K., Verburg L., Blondal J., Mowat M. R., Israels L. G., Begleiter A. Induction of apoptosis in CD4+ prolymphocytic leukemia by deoxyadenosine and 2′-deoxycoformycin. Leuk. Res. 1992; 16: 781–788
   PubMed Web of Science ®Google Scholar
• Harlow L., Lane D. Antibodies: A Laboratory Manual. 1988, Cold Spring Harbor Laboratory Press.
   Google Scholar
• Chomczynski P., Sacchi N. Single-step method of RNA isolation by acid guanidium thiocyanate-phenol-chloro-form extraction. Anal. Biochem. 1987; 162: 156–159
   PubMed Web of Science ®Google Scholar
• Church G. M., Gilbert W. Genomic sequencing. Proc. Natl. Acad. Sci. U.S.A. 1984; 81: 1991–1995
   PubMed Web of Science ®Google Scholar
• Kocialkowski S., Pezzela F., Morrison H., Jones M., Laha S., Harris A. L., Mason D. Y., Gatter K. C. Mutations in the p53 gene are not limited to classic ‘hot spots’ and are not predictive of p53 protein expression in high-grade non-Hodgkin's lymphoma. Br. J. Haematol. 1995; 89: 55–60
   PubMed Web of Science ®Google Scholar
• Kasuga T., Cheng J., Mitchelson K. R. Metastable single-strand DNA conformational polymorphism analysis results in enhanced polymorphism detection. In. PCR Methods and Applications. 1995; 277–233, pp. Cold Spring Harbor Laboratory Press.
   Google Scholar
• Peng H., Du M., Ji J., Isaacson P. G., Pan L. High-resolution SSCP analysis using polyacrylamide agarose composite gel and a background-free silver staining method. Biotechniques 1995; 19: 411–414
   Google Scholar
• Nakamura H., Said J. W., Miller C. W., Koeffler H. P. Mutation and protein expression of p53 in acquired immunodeficiency syndrome-related syndrome. Blood 1993; 82: 920–926
   PubMed Web of Science ®Google Scholar
• Resnick J. M., Cherwitz D., Knapp D. A microwave method that enhances detection of aberrant p53 expression in formalin-fixed, paraffin-embedded tissues. Arch. Pathol. Lab. Med. 1995; 119: 360–366
   PubMed Web of Science ®Google Scholar
• Lu X., Lane D. P. Differential induction of tran-scriptionally active p53 following U. V. or ionizing radiation: Defects in chromosome instability syndromes?. Cell 1993; 75: 765–778
   PubMed Web of Science ®Google Scholar
• Zhan Q., Fan S., Bae I., Guillouf C., Liebermann D. A., O'Connor P. M., Fornace A. J. Induction of bax by genotoxic stress in human cells correlates with normal p53 status and apoptosis. Oncogene 1994; 9: 3743–3751
   PubMed Web of Science ®Google Scholar
• McConkey D. J., Chandra J., Wright S., Plunkett W., McDonnell T. J., Reed J. C., Keating M. Apoptosis sensitivity in chronic lymphocytic leukemia is determined by endogenous endonuclease content and relative expression of BCL-2 and BAX. J. Immunol. 1996; 156: 2624–2630
   PubMed Web of Science ®Google Scholar
• Thomas A., El Rouby S., Reed J. C., Krajewski S., Silber R., Potmesil M., Newcomb E. W. Drug-induced apoptosis in B-cell chronic lymphocytic leukemia: relationship between p53 gene mutation and bcl-2/bax proteins in drug resistance. Oncogene 1996; 12: 1055–1062
   PubMed Web of Science ®Google Scholar
• Campos L., Rouault J.-P., Sabido O., Oriol P., Roubi N., Vasseon C., Archimbaud E., Magaud J.-P., Guyotat D. High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood 1993; 81: 3091–3096
   PubMed Web of Science ®Google Scholar
• Maung Z. T., Maclean F. R., Reid M. M., Pearson A. D. J., Proctor S. J., Hamilton P. J., Hall A. G. The relationship between bcl-2 expression and response to chemotberapy in acute leukaemia. Br. J. Haematol. 1995; 88: 105–109
   Web of Science ®Google Scholar